Veracyte Stock Crosses Below 200-Day Moving Average

Analysts Weigh In on Biotech Firm's Declining Share Price

Apr. 9, 2026 at 8:33am

Got story updates? Submit your updates here. ›

A high-contrast, close-up image of a complex, industrial-looking financial mechanism, such as gears, levers, or electronic components, conveying a sense of the intricate infrastructure that underpins the financial system.As Veracyte's stock price crosses below its 200-day moving average, the complex financial mechanisms that drive the biotech industry are exposed, raising questions about the company's long-term outlook.South San Francisco Today

Shares of Veracyte, Inc. (NASDAQ:VCYT), a genomic diagnostics company, have fallen below their 200-day moving average, raising questions about the stock's performance. The company's stock price closed at $32.67 on Wednesday, with over 826,000 shares traded.

Why it matters

Veracyte's stock price crossing below the 200-day moving average is a technical indicator that can signal a potential downward trend. This development may concern investors and prompt a closer look at the company's fundamentals and market position.

The details

Several research firms have commented on Veracyte's stock, with Zacks Research downgrading the shares from a 'strong-buy' to a 'hold' rating. Wall Street Zen, on the other hand, upgraded the stock from 'buy' to 'strong-buy'. Analysts have a mixed outlook, with a consensus 'Hold' rating and an average price target of $44.20.

  • Veracyte's stock price crossed below its 200-day moving average of $38.30 during trading on Wednesday, April 9, 2026.

The players

Veracyte, Inc.

A genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing.

Zacks Research

A research firm that has downgraded Veracyte's stock from a 'strong-buy' to a 'hold' rating.

Wall Street Zen

A research firm that has upgraded Veracyte's stock from 'buy' to 'strong-buy'.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely monitoring Veracyte's stock performance and any further developments that may impact the company's outlook.

The takeaway

Veracyte's stock price crossing below the 200-day moving average is a technical indicator that may signal a potential downward trend. Analysts have a mixed outlook on the company, with a consensus 'Hold' rating, suggesting the need for a closer examination of Veracyte's fundamentals and market position.